Tesamorelin Side Effects: Common, Serious, and What to Report

These rates come from the approved product's label, which pools data from 740 treated patients, 543 of them in the 26-week placebo-controlled phase. The medications this page covers:

Every price is all-in: medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. An approved tesamorelin product exists for one indication; compounded tesamorelin is not FDA approved, and compounded medications are not FDA approved. The rates on this page belong to the approved product, which contains the same active peptide.

Tesamorelin is the full 44-amino-acid sequence of growth-hormone-releasing hormone (GHRH), the signal the hypothalamus sends to the pituitary, with a cap that protects it from being broken down. It binds the GHRH receptor and prompts a pulse of your own growth hormone, which works in adults largely through IGF-1 made in the liver. It contains no growth hormone, and the body's brakes, somatostatin and IGF-1 feedback, keep working.

Almost every side effect is that mechanism. Growth hormone makes the body hold more fluid, which shows up as puffiness, joint aches, swelling and tingling. Growth hormone reduces insulin sensitivity, which is the reason for the blood sugar warning. And like any injected peptide, it can irritate the skin where it goes in or, rarely, provoke an allergic reaction. In the trials, IGF-1 rose by 81% in one study and 117% in another while staying within the physiological range; the aim is a physiological level, not the highest one achievable.

This is the side effect to understand before starting. Growth hormone reduces insulin sensitivity, so tesamorelin can raise blood glucose. In the trials there were no clinically meaningful group differences in glucose at 26 or 52 weeks, and the one trial outside HIV, in 60 abdominally obese adults over 12 months, reported no change in glucose measures. But the approved label records new-onset diabetes in 5% of treated patients against 1% on placebo.

Symptoms of raised blood sugar to report include unusual thirst and passing urine more often. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

The label figures were recorded at a higher daily dose than Pepti's directions, and the fluid-related effects are associated with growth hormone levels above what a person needs. Whether the rates are lower at 0.5 mg on weekdays has not been studied, so this page does not claim they are. The current approved formulation is dosed at 1.28 mg once daily. Its label also states that long-term cardiovascular safety has not been established.

Tesamorelin appears in several Pepti blends, and in a blend the side effects are those of every ingredient. Each is a 5 mL vial drawn at 0.25 mL.

If you are prescribed a blend, read its label and its own page rather than assuming it behaves like tesamorelin alone. The blends are compared in what is tesamorelin + ipamorelin and physiq vs shred vs titan. Every dose and every blend is set out in tesamorelin dosage.

If the side effects above are a concern, the alternatives have their own profiles. Sermorelin is a shorter-acting GHRH analogue on the same receptor, so it shares the class cautions. MOTS-c works through a different, non-pituitary pathway and does not carry the growth-hormone fluid effects. For weight on the scale, which tesamorelin's label calls weight-neutral, semaglutide and tirzepatide have far more evidence, with their own side effects. How they compare: sermorelin vs tesamorelin vs ipamorelin, MOTS-c vs tesamorelin, AOD-9604 vs tesamorelin and tesamorelin vs semaglutide.

Tesamorelin's side-effect profile is better characterised than that of almost any other compounded peptide, because it comes from randomised, double-blind, placebo-controlled trials, including two phase 3 trials that supported an FDA approval, and a label that pools 740 treated patients. The common effects, the glucose warning and the contraindications are documented rather than inferred.

The limits are real. The trial rates belong to the approved product at 1 to 2 mg daily, not to a compounded preparation at 0.5 mg on weekdays. The trials enrolled mostly people with HIV, ran 12 months at most, and say nothing about long-term cardiovascular safety, which the label itself says has not been established. And no trial has enrolled healthy, non-overweight adults with normal growth hormone secretion. Read the placebo column first: 11% of people on a dummy injection reported joint pain, so not everything you feel on tesamorelin is the drug.

One risk specific to compounded vials is dosing error, which is why Pepti prints the dose in both millilitres and syringe units for the exact vial you receive. If the label does not match what you expected, do not inject; message your care team. The benefit side of the same trials is in tesamorelin benefits.

Tesamorelin cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and dose questions. Refills run every 28 days, one vial per fill.

Pepti prescribes tesamorelin in every state except Oklahoma, plus DC Step by step: how to get tesamorelin prescribed online.